Outcome in transplant eligible patients with multiple myeloma in Latin America. An international study of GELAMM

Outcome in transplant eligible patients with multiple myeloma in Latin America. An international study of GELAMM


Authors:
 

Camila Peña, Natalia P Schutz, Virginia Bove, Fiorella Villano, Rocío Osorio, Mauricio Chandía, Daniela Cardemil, Carolina Contreras, Carmen G Contreras, Javiera Donoso, Marcela Espinoza, La Rocca Gabriel, Hernán López-Vidal, Christine Rojas, Pablo Soto, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Sebastián Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Quiroga, Carlos Alen García, Vanesa Fernández, Dorotea Fantl, Eloísa Riva

Abstract:

Multiple myeloma (MM) is a frequent hematologic malignancy. Despite the important advances in treatment strategies during the last decades, the gold standard remains being a proteasome inhibitor (PI)-based induction, followed by autologous stem cell transplant (ASCT).

In Latin America (LA) there is great heterogeneity in access to new drugs and ASCT, and there is scarce data regarding patient ´s outcomes in the region.

Publication:

EHA Library. Peña C. 06/15/19; 267019; PS1402

 

 

 

 

 

Age does not confer different features and outcomes in patients with newly diagnosed active multiple myeloma younger that 66 years if age treated in a recent period

Authors:

Virginia Bove, Sabrina Ranero,, Fiorella Villano, Eloisa Riva
Hematology , Hospital de Clinicas, Montevideo, Uruguay

Abstract:

Multiple myeloma (mm) is a disease of the elderly, with median age at diagnosis of 66 years. However, 10% of patients are younger than 50 years.

Publications regarding age as prognostic factor for clinical characteristics at diagnosis and outcomes are heterogeneous, with some authors reporting aggressive presentation and worse outcomes in young patients and others showing better outcomes.